No good

2
Comment
Favorite

Tonica
2022-05-10

No good

Novavax Posts First Quarterly Profit, but Misses Expectations

Vaccine maker keeps 2022 revenue guidance intactShares of Novavax Inc. dropped more than 18% in the

Novavax Posts First Quarterly Profit, but Misses Expectations

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9065991059,"tweetId":"9065991059","gmtCreate":1652138114071,"gmtModify":1676535035636,"author":{"id":4093583449913140,"authorId":4093583449913140,"authorIdStr":"4093583449913140","name":"Tonica","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":24,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>No good</p></body></html>","htmlText":"<html><head></head><body><p>No good</p></body></html>","text":"No good","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9065991059","repostId":2234504689,"repostType":4,"repost":{"id":"2234504689","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1652136651,"share":"https://www.laohu8.com/m/news/2234504689?lang=&edition=full","pubTime":"2022-05-10 06:50","market":"us","language":"en","title":"Novavax Posts First Quarterly Profit, but Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2234504689","media":"Dow Jones","summary":"Vaccine maker keeps 2022 revenue guidance intactShares of Novavax Inc. dropped more than 18% in the ","content":"<html><head></head><body><p>Vaccine maker keeps 2022 revenue guidance intact</p><p>Shares of Novavax Inc. dropped more than 18% in the extended session Monday after the biotech company reported its first profitable quarter, but not by as much as Wall Street expected, and its sales were also below estimates.</p><p><img src=\"https://static.tigerbbs.com/ee81b2f2acc1426f7fd21faf826b0233\" tg-width=\"840\" tg-height=\"618\" referrerpolicy=\"no-referrer\"/></p><p>Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted a emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Posts First Quarterly Profit, but Misses Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Posts First Quarterly Profit, but Misses Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-05-10 06:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Vaccine maker keeps 2022 revenue guidance intact</p><p>Shares of Novavax Inc. dropped more than 18% in the extended session Monday after the biotech company reported its first profitable quarter, but not by as much as Wall Street expected, and its sales were also below estimates.</p><p><img src=\"https://static.tigerbbs.com/ee81b2f2acc1426f7fd21faf826b0233\" tg-width=\"840\" tg-height=\"618\" referrerpolicy=\"no-referrer\"/></p><p>Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.</p><p>Revenue rose to $704 million, from $447 million a year ago.</p><p>Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.</p><p>Novavax said it has been &#34;successful&#34; in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.</p><p>&#34;Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,&#34; Chief Executive Stanley C. Erck said in a statement.</p><p>Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.</p><p>The company has submitted a emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration&#39;s advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2234504689","content_text":"Vaccine maker keeps 2022 revenue guidance intactShares of Novavax Inc. dropped more than 18% in the extended session Monday after the biotech company reported its first profitable quarter, but not by as much as Wall Street expected, and its sales were also below estimates.Novavax said it earned $203 million, or $2.56 a share, in the quarter, swinging from a net loss of $223 million, or $3.05 a share, in the year-ago period.Revenue rose to $704 million, from $447 million a year ago.Analysts polled by FactSet expected Novavax to report earnings of $2.69 a share on sales of $845 million.Novavax said it has been \"successful\" in launching its COVID-19 vaccine worldwide and it is on track to expand its label use.\"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-influenza combination vaccine candidate,\" Chief Executive Stanley C. Erck said in a statement.Novavax also reiterated its 2022 revenue guidance of between $4 billion and $5 billion.The company has submitted a emergency-use authorization request for its COVID-19 vaccine, with the U.S. Food and Drug Administration's advisory committee scheduled to meet June 7. The vaccine is authorized in a few other countries.","news_type":1},"isVote":1,"tweetType":1,"viewCount":182,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}